Shionogi, a leading Japanese pharmaceutical company, has joined the CMAC consortium, marking a pivotal step in global collaboration and innovation. Renowned for addressing unmet medical needs, Shionogi brings valuable regulatory insights and deep scientific expertise to CMAC’s international network.
Read MoreA new £1m research project to realise the transformative potential of digital technologies like artificial intelligence (AI) in medicines development and manufacturing has been announced.
The Centre of Excellence in Regulatory Science and Innovation (CERSI) project aims to advance regulatory processes by integrating cutting-edge digital technologies.
Read MoreTogether, CMAC and digiM will align to accelerate research and development within CMAC’s ambitious strategy for digital transformation of Chemistry, Manufacturing, and Control (CMC) processes.
Read MoreIn a significant stride towards advancing nanoparticle drug delivery manufacturing technology, leon-nanodrugs GmbH (LEON), has proudly announced a pioneering technical evaluation by CMAC, University of Strathclyde.
Read MoreCMAC are thrilled to announce that we have welcomed Malvern Panalytical as a new Tier 2 member within our cutting-edge technology portfolio.
Read MoreThis collaboration marks a significant milestone for the Centre in driving collaborative research and innovation within advanced pharmaceutical manufacturing.
Read MoreThe University of Strathclyde’s medicines manufacturing research centre, CMAC, is delighted to announce the next phase in our strategic partnership with The Glasgow School of Art (GSA).
Read More
